Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Achilles Therapeutics Provides Interim Phase 1/2a Update on Clonal Neoantigen Reactive T Cells In Advanced NSCLC And Melanoma Including First Patients Dosed with Enhanced Host Conditioning

Author: Benzinga Newsdesk | April 04, 2024 05:32am
  • Improved VELOS manufacturing process delivering higher cNeT doses.
  • Protocols updated to evaluate the benefit of enhanced host conditioning, with further data expected in 2H 2024.
  • First three patients dosed in CHIRON and THETIS with enhanced host chemo-conditioning, along with IL-2 aligned to standard TIL therapy, show improved cNeT persistence and engraftment.

Posted In: ACHL


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist